OverviewSuggest Edit
23andMe is a personal genetics company dedicated to helping individuals understand their own genetic information through DNA analysis technologies and web-based interactive tools. The Company's Personal Genome Service enables individuals to gain deeper insights into their ancestry and genetic make-up. The vision for 23andMe is to personalize healthcare by making and supporting meaningful discoveries through genetic research.
| Type | Private | |
| Founded | 2006 | |
| HQ | Mountain View, US | Map |
| Website | 23andme.com | |
| Employee Ratings | More |
Latest Updates
| Employees (est.) (Mar 2019) | 672 | (+2%) |
| Job Openings | 46 |
Key People/Management at 23andMe
Anne Wojcicki
CEO and Co-Founder
Richard Scheller
Chief Science Officer & Head of Therapeutics
Joyce Tung
Vice President, Research
Emily Drabant Conley
Vice President, Business Development
Kathy Hibbs
Chief Legal and Regulatory Officer
Jonathan Ward
Vice President, Consumer Marketing | Acquisition
Report incorrect company information
23andMe Office Locations
23andMe has an office in Mountain View
Mountain View, US (HQ)
899 W Evelyn Ave
Report incorrect company information
23andMe Financials and Metrics
Summary Metrics
Founding Date | 2006 |
23andMe total Funding | $829.5 m |
23andMe latest funding size | $300 m |
Time since last funding | 8 months ago |
23andMe investors | Altimeter Capital, Stephens Investment Management, Anne Wojcicki, GlaxoSmithKline, WuXi Healthcare Ventures, GV, Wallenberg Foundations, Genentech, Fidelity Investments, EquityZen, Xfund, Euclidean Capital, National Institutes of Health, Sequoia Capital, New Enterprise Associates, Johnson & Johnson Development Corporation, Illumina, Mohr Davidow Ventures, Google, DST Global, MPM Capital, Sergey Brin, Casdin Capital |
23andMe's latest funding round in July 2018 was reported to be $300 m. In total, 23andMe has raised $829.5 m. 23andMe's latest valuation is reported to be $1.7 b.
23andMe Revenue
Market valuation | 1.7b |
- Source: Sharespost
23andMe Operating Metrics
23andMe's Customers was reported to be 5 m in Jul, 2018.
| Y, 2015 | Y, 2017 | Jul, 2018 | |
|---|---|---|---|
Countries | 50 | ||
Customers | 800 k | 2 m | 5 m |
Phenotypic Data Points Collected | 600 m |
Report incorrect company information
23andMe Online and Social Media Presence
90.15k Twitter followers
23andMe has 90.15k Twitter Followers. The number of followers has increased 0.3% month over month and increased 1.9% quarter over quarter
Report incorrect company information
Twitter Engagement Stats for @23andMe
17.3k
Tweets
7.3k
Following
90.1k
Followers
89
Tweets last 30 days
13.1
Avg. likes per Tweet
95.5%
Tweets with engagement
23andMe News and Updates
March 11, 2019
Brainstorm Health: 23andMe and Diabetes, Death by Video Chat, Trump Budget
Brainstorm Health Daily: March 11, 2019
March 11, 2019
23andMe Plans New Genetic Test on Risk of Getting Diabetes
One in three Americans is pre-diabetic.
March 10, 2019
23andMe is hoping to reach millions more users with a new genetic report on diabetes
23andMe is adding a report to its health and ancestry DNA test for type 2 diabetes. That's a huge market opportunity as 1 in 3 people are at risk for developing the disease. More than 30 million people in the U.S. alone have diabetes.
March 10, 2019
23andMe Offers New Genetic Report on Type 2 Diabetes
MOUNTAIN VIEW, Calif., March 10, 2019 /PRNewswire/ -- 23andMe, Inc., the leading personal genetics company, will begin offering a new genetic Health Predisposition report on type 2 diabetes. The report offers customers insight into their likelihood of developing one of the most common,...
February 16, 2019
After you spit into a tube for a DNA test like 23andMe, experts say you shouldn't assume your data will stay private forever
It may be getting easier to link your private and anonymized DNA data to your identity.
That means the genetic data you share with a testing company — which may include sensitive health information like your risk of cancer — could one day be matched with your name by an unintended party.
While som…
February 14, 2019
23andMe is upending how we find new drugs, and the CEO says 13 are now in early trials
Silicon Valley genetic testing startup 23andMe is making progress in its efforts to develop new drugs for everything from skin conditions to cancer and heart disease, the CEO said at an event last week.
Therapeutics with the 23andMe label would be a "source of pride" for the company, she added.
2…
Report incorrect company information
23andMe Frequently Asked Questions
When was 23andMe founded?
23andMe was founded in 2006.
Who are 23andMe key executives?
23andMe's key executives are Anne Wojcicki, Richard Scheller and Joyce Tung.
How many employees does 23andMe have?
23andMe has 672 employees.
Who are 23andMe competitors?
Competitors of 23andMe include Myriad Genetics, Complete Genomics and Natera.
Where is 23andMe headquarters?
23andMe headquarters is located at 899 W Evelyn Ave, Mountain View.
Where are 23andMe offices?
23andMe has an office in Mountain View.
How many offices does 23andMe have?
23andMe has 1 office.